FDA Issues New Vision Loss Warning for GLP-1 Weight Loss Drugs: What Patients Need to Know
Weight LossDiabetes Management

FDA Issues New Vision Loss Warning for GLP-1 Weight Loss Drugs: What Patients Need to Know

avinashmittal

Published November 10, 2026

On November 9, 2026, the U.S. Food and Drug Administration (FDA) required makers of all GLP-1 medications, including Ozempic, Wegovy, Mounjaro and Zepbound, to add a new warning about a rare eye condition that can cause sudden vision loss. The condition is called non-arteritic anterior ischemic optic neuropathy, or NAION. The FDA describes the risk as potential, and NAION remains uncommon. Still, millions of Americans take these drugs for diabetes or weight management, so knowing the warning signs could help protect someone’s sight.

FDA Announces a New GLP-1 Safety Warning

In a Drug Safety Communication, the FDA said it is requiring every GLP-1 receptor agonist manufacturer to add information about a potential increased risk of NAION to the “Warnings and Precautions” section of the drug label. The agency said NAION cases have been reported with all currently marketed GLP-1 products.

The update doesn’t mean these medications are unsafe for most people, and it doesn’t tell anyone to stop treatment. It does mean patients, caregivers and clinicians should know the symptoms and act quickly if vision suddenly changes.

What Are GLP-1 Weight Loss Drugs?

GLP-1 receptor agonists mimic glucagon-like peptide-1, a hormone the gut releases after eating. These drugs:

  • Help the pancreas release insulin when blood sugar is high, improving blood glucose control in type 2 diabetes (see what a normal A1C is)
  • Slow stomach emptying, so people feel full longer
  • Act on appetite centers in the brain, reducing hunger and supporting weight loss

Depending on the specific drug, FDA-approved uses also include lowering the risk of heart attack and stroke in certain patients, slowing chronic kidney disease, treating obstructive sleep apnea in adults with obesity, and treating a fatty liver disease called MASH.

Common GLP-1 medications

  • Semaglutide: Ozempic and Rybelsus (diabetes), Wegovy (weight management and heart risk)
  • Tirzepatide: Mounjaro (diabetes) and Zepbound (weight management and sleep apnea)
  • Others: Trulicity (dulaglutide), Victoza and Saxenda (liraglutide), combination products Xultophy and Soliqua, Foundayo, and generic exenatide

Tirzepatide is technically a dual-acting drug. It activates both GIP and GLP-1 receptors. Because of its GLP-1 activity, it’s included in the new warning.

What Is NAION? Understanding the “Eye Stroke”

The optic nerve carries visual signals from the eye to the brain. In NAION, blood flow to the front part of this nerve suddenly drops. Without enough oxygen, nerve fibers swell and can be damaged. That’s why the condition is often called an “eye stroke.”

NAION typically causes sudden, painless vision loss in one eye, often noticed on waking. Some people regain a little vision, but in many cases the damage is permanent. There is currently no proven treatment to reverse it. According to the FDA, NAION occurs in roughly 2 to 10 per 100,000 adults over 50 each year, even without these medications.

Why Has the FDA Issued This Warning?

Concern grew after a 2024 study in JAMA Ophthalmology from Massachusetts Eye and Ear. It found that patients prescribed semaglutide had a higher rate of NAION than similar patients on other medications. The FDA noted that the study had “several limitations.” That’s typical for single-center observational research, but the agency decided the signal deserved a full review.

The FDA then examined several types of evidence:

  • Randomized clinical trials: a pooled analysis of 126 trials (details below)
  • Real-world data: the FDA’s Sentinel system compared GLP-1 users with type 2 diabetes against users of other diabetes drugs. NAION was more common than with DPP-4 inhibitors (hazard ratio 1.43), but the difference compared with SGLT-2 inhibitors wasn’t statistically significant (hazard ratio 1.19).
  • Published observational studies: the FDA said the better-designed studies consistently found higher NAION risk with GLP-1 drugs than with DPP-4 or SGLT-2 inhibitors.
  • Adverse event reports: hard to interpret, because NAION risk factors such as diabetes and sleep apnea are common among GLP-1 users.
  • Animal data: no biological mechanism was identified.

Association versus causation: together, this evidence points to a possible increased risk. It does not prove that GLP-1 drugs cause NAION, and the FDA’s communication doesn’t claim they do. A label warning lets patients and doctors act on a credible signal while research continues.

What Did the FDA’s Clinical Trial Analysis Show?

The FDA pooled 126 randomized controlled trials with 134,253 participants. That included 78,217 people taking a GLP-1 drug and 56,036 taking a placebo or another diabetes medicine.

  • Total probable NAION cases: 15. Ten were in GLP-1 users and five were in placebo groups.
  • GLP-1 users: 6.4 cases per 100,000 person-years
  • Comparison groups: 3.8 cases per 100,000 person-years

What those numbers mean

A “person-year” is one person followed for one year. A rate of 6.4 per 100,000 person-years means that if 100,000 people took a GLP-1 drug for a year, you might expect about six NAION cases. In a similar comparison group, you might expect about four. That’s not your personal lifetime risk, and it doesn’t predict what will happen to any individual.

Because NAION is so rare, these trials recorded very few cases. That makes precise estimates difficult. Small numbers also explain why the FDA looked at real-world data, where rates are higher because patients tend to be older and have more risk factors.

Which Weight Loss and Diabetes Drugs Are Affected?

The warning is class-wide. It covers every GLP-1 receptor agonist the FDA listed, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda, Xultophy, Soliqua and Foundayo. A class-wide warning reflects the shared way these drugs work. It doesn’t mean every product carries the same level of risk, or that every patient will have vision problems. The vast majority of people taking these medicines won’t develop NAION.

What Are the Warning Signs of NAION?

The FDA advises contacting a healthcare professional right away if you notice:

  • Sudden vision loss in one eye, often noticed upon waking
  • Blurry or hazy vision, especially in the center
  • Blind spots or dark areas in your field of vision
  • Tunnel vision or loss of side or lower vision
  • Colors looking faded or distorted
  • Any other sudden, unexplained change in vision

Sudden vision loss can also signal other emergencies, such as a retinal detachment or a stroke. Don’t wait to see whether it improves.

Who May Have a Higher Risk of NAION?

The FDA lists these known risk factors:

  • Diabetes
  • High blood pressure
  • Smoking
  • Obstructive sleep apnea
  • Anemia
  • Kidney disease
  • A previous NAION episode, which raises the risk for the other eye

Eye specialists also recognize a “crowded” optic disc, a small optic nerve opening that’s present from birth, as a contributing anatomical factor. Many of these conditions are common in people prescribed GLP-1 drugs. That overlap is one reason the true size of any drug-related risk is hard to pin down. If you have several of these factors, ask your doctor how they apply to you.

What Medical Experts and Drug Manufacturers Say

Independent experts

Manjot Gill, MD, an ophthalmologist at Northwestern Medicine, told ABC News that the warning was appropriate. She added that it mainly serves to raise awareness, because the condition is extremely rare. Many experts agree that more research is needed. Large studies designed specifically to measure NAION would help clarify whether the risk differs by drug, dose or patient group.

Novo Nordisk

Novo Nordisk, which makes Ozempic, Wegovy and Rybelsus, said the evidence does not establish cause and effect, and that it remains confident in the benefit-risk balance of its medicines. The company also told The Washington Post that an analysis of more than 90,000 clinical trial participants found no association.

Eli Lilly

Eli Lilly, which makes Mounjaro and Zepbound, told CNN that the FDA’s communication applies to all GLP-1 drugs and doesn’t cite findings specific to Lilly products. The company said it is evaluating the update and will respond to the agency promptly.

Both companies have a financial stake in these drugs and face lawsuits from patients alleging vision loss. Their statements are company positions, not independent scientific conclusions.

Should Patients Stop Taking GLP-1 Medications?

No, not without talking to your doctor first. These drugs can provide significant benefits, including better blood sugar control, weight loss, and, for some patients, lower heart and kidney risk. Stopping suddenly can cause blood sugar to rise or weight to return.

  • If you have no vision symptoms: keep taking your medication as prescribed, and ask about the new warning at your next visit.
  • If you notice sudden vision changes: contact a healthcare professional immediately. The FDA advises clinicians to refer suspected NAION promptly to an ophthalmologist.
  • If you’ve been diagnosed with NAION: talk with your prescriber about whether to continue. The FDA tells clinicians to consider stopping the GLP-1 drug unless its benefits clearly outweigh the risk.

Every treatment decision should weigh your own benefits and risks.

How Can Patients Protect Their Vision?

No step can guarantee you won’t develop NAION, but these measures support eye health and earlier action:

  • Know the symptoms and treat any sudden vision change as urgent.
  • Manage blood pressure, blood sugar and sleep apnea, and stop smoking if you smoke.
  • Keep up with eye exams. People with diabetes are generally advised to have regular dilated eye exams.
  • Share your full health history, including any previous eye problems, with your prescriber.
  • Stay active and keep regular checkups. Our guides on daily step goals and how often to get a physical can help.

Suspected side effects can be reported to the FDA’s MedWatch program online or at 1-800-332-1088.

What the Warning Means for the Future of Weight Loss Drugs

  • Safety monitoring: the review shows how post-marketing surveillance, including the FDA’s Sentinel system, can pick up rare risks that trials are too small to detect.
  • Manufacturers: companies must update labels and may face pressure to run studies designed to measure eye outcomes.
  • Prescribers: doctors will likely spend more time discussing vision symptoms and eye risk factors, especially with patients who have had NAION or several risk factors.
  • Patients: people considering GLP-1 treatment now have clearer information for an informed decision.
  • Research: scientists still need to understand whether there’s a biological mechanism, and whether risk varies by drug, dose or speed of blood sugar change.

Conclusion

The FDA’s new requirement adds NAION to the warnings for every GLP-1 medication, from Ozempic and Wegovy to Mounjaro and Zepbound. The evidence suggests a potential increase in a condition that is rare but can permanently affect vision. It does not prove the drugs cause it. For most people, the practical message is simple: keep taking your medicine as prescribed, learn the warning signs, and seek care immediately if your vision suddenly changes. Bring any concerns to your prescriber or an eye specialist, who can weigh your personal risks and benefits.

Find more evidence-based health guides on Learning Joan.

This article is for general information only and is not a substitute for professional medical advice. Do not stop or change any prescribed medication without talking to your healthcare provider.